Michael J Osgood1, Kevin Sexton1, Igor Voskresensky1, Kyle Hocking2, Jun Song1, Padmini Komalavilas3, Colleen Brophy3, Joyce Cheung-Flynn4. 1. Department of Surgery, Vanderbilt University, Nashville, Tenn. 2. Department of Surgery, Vanderbilt University, Nashville, Tenn; Department of Biomedical Engineering, Vanderbilt University, Nashville, Tenn. 3. Department of Surgery, Vanderbilt University, Nashville, Tenn; Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tenn. 4. Department of Surgery, Vanderbilt University, Nashville, Tenn. Electronic address: joyce.cheung-flynn@vanderbilt.edu.
Abstract
BACKGROUND: Intimal hyperplasia remains the primary cause of vein graft failure for the 1 million yearly bypass procedures performed using human saphenous vein (HSV) grafts. This response to injury is caused in part by the harvest and preparation of the conduit. The use of Brilliant Blue FCF (FCF) restores injury-induced loss of function in vascular tissues possibly via inhibition of purinergic receptor signaling. This study investigated whether pretreatment of the vein graft with FCF prevents intimal hyperplasia. METHODS: Cultured rat aortic smooth muscle cells (A7r5) were used to determine the effect of FCF on platelet-derived growth factor-mediated migration and proliferation, cellular processes that contribute to intimal hyperplasia. The effectiveness of FCF treatment during the time of explantation on preventing intimal hyperplasia was evaluated in a rabbit jugular-carotid interposition model and in an organ culture model using HSV. RESULTS: FCF inhibited platelet-derived growth factor-induced migration and proliferation of A7r5 cells. Treatment with FCF at the time of vein graft explantation inhibited the subsequent development of intimal thickening in the rabbit model. Pretreatment with FCF also prevented intimal thickening of HSV in organ culture. CONCLUSIONS: Incorporation of FCF as a component of vein graft preparation at the time of explantation represents a potential therapeutic approach to mitigate intimal hyperplasia, reduce vein graft failure, and improve outcome of the autologous transplantation of HSV.
BACKGROUND: Intimal hyperplasia remains the primary cause of vein graft failure for the 1 million yearly bypass procedures performed using human saphenous vein (HSV) grafts. This response to injury is caused in part by the harvest and preparation of the conduit. The use of Brilliant Blue FCF (FCF) restores injury-induced loss of function in vascular tissues possibly via inhibition of purinergic receptor signaling. This study investigated whether pretreatment of the vein graft with FCF prevents intimal hyperplasia. METHODS: Cultured rat aortic smooth muscle cells (A7r5) were used to determine the effect of FCF on platelet-derived growth factor-mediated migration and proliferation, cellular processes that contribute to intimal hyperplasia. The effectiveness of FCF treatment during the time of explantation on preventing intimal hyperplasia was evaluated in a rabbit jugular-carotid interposition model and in an organ culture model using HSV. RESULTS:FCF inhibited platelet-derived growth factor-induced migration and proliferation of A7r5 cells. Treatment with FCF at the time of vein graft explantation inhibited the subsequent development of intimal thickening in the rabbit model. Pretreatment with FCF also prevented intimal thickening of HSV in organ culture. CONCLUSIONS: Incorporation of FCF as a component of vein graft preparation at the time of explantation represents a potential therapeutic approach to mitigate intimal hyperplasia, reduce vein graft failure, and improve outcome of the autologous transplantation of HSV.
Authors: B Kumar; K Dreja; S S Shah; A Cheong; S-Z Xu; P Sukumar; J Naylor; A Forte; M Cipollaro; D McHugh; P A Kingston; A M Heagerty; C M Munsch; A Bergdahl; A Hultgårdh-Nilsson; M F Gomez; K E Porter; P Hellstrand; D J Beech Journal: Circ Res Date: 2006-01-26 Impact factor: 17.367
Authors: Eric S Wise; Kyle M Hocking; Weifeng Luo; Daniel L Feldman; Jun Song; Padmini Komalavilas; Joyce Cheung-Flynn; Colleen M Brophy Journal: Vasc Med Date: 2016-05-23 Impact factor: 3.239
Authors: Joyce Cheung-Flynn; Jun Song; Igor Voskresensky; Eric S Wise; Yapu Liu; Yanhua Xiong; Susan S Eagle; Colleen M Brophy; C Robb Flynn Journal: Sci Rep Date: 2017-10-27 Impact factor: 4.379